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Objectives: We sought to identify factors associated with need for mechanical ventilation (MV), length 
of intensive care unit (ICU) stay, length of hospital stay, and poor outcome in injection drug users 
(IDUs) with wound botulism (WB).
Methods: This is a retrospective review of WB patients admitted between 1991-2005. IDUs were 
included if they had symptoms of WB and diagnostic confirmation. Primary outcome variables were 
the need for MV, length of ICU stay, length of hospital stay, hospital-related complications, and death.
Results: Twenty-nine patients met inclusion criteria. Twenty-two (76%) admitted to heroin use 
only and seven (24%) admitted to heroin and methamphetamine use. Chief complaints on initial 
presentation included visual changes, 13 (45%); weakness, nine (31%); and difficulty swallowing, 
seven (24%). Skin wounds were documented in 22 (76%). Twenty-one (72%) patients underwent 
mechanical ventilation (MV). Antitoxin (AT) was administered to 26 (90%) patients but only two 
received antitoxin in the emergency department (ED). The time from ED presentation to AT 
administration was associated with increased length of ICU stay (Regression coefficient = 2.5; 95% 
CI 0.45, 4.5). The time from ED presentation to wound drainage was also associated with increased 
length of ICU stay (Regression coefficient = 13.7; 95% CI = 2.3, 25.2). There was no relationship 
between time to antibiotic administration and length of ICU stay. 
Conclusion: MV and prolonged ICU stays are common in patients identified with WB. Early AT 
administration and wound drainage are recommended as these measures may decrease ICU length 
of stay. [West J Emerg Med. 2009;10(4):251-256.]
INTRODUCTION
Background
Six reported forms of botulism exist, including food 
borne, infantile, wound, iatrogenic, adult infectious (in vivo 
adult intestinal colonization), and inhalational. Infantile 
botulism is the most frequently reported form, followed by 
wound botulism. Although wound botulism remains a rare 
diagnosis, its incidence has been rising. 1,2,3 In California, 
where the majority of wound botulism cases have occurred, an 
average of 0.5 cases per year were reported from 1951-1987. 
However, from 1987-1998 there was a 20-fold increase to 
9.9 cases per year.4 Early wound botulism cases were related 
to deep tissue infections in avascular body locations, until 
the mid-1980s when the first cases associated with injection 
drug use (IDU were reported. Since then, the vast majority 
of wound botulism cases are related to IDU.1,4 Although 
the reasons are not well understood, the majority of wound 
botulism cases originate in California. 1,2 To date, the largest 
reported series of wound botulism from injection drug use 
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health records between 1951-1998. Remarkably, 114 (87%) of 
these cases were diagnosed in California. The extraordinarily 
high number of wound botulism cases reported in California 
was attributed to black tar heroin imported illicitly from 
Mexico, although a definite causal association could not be 
made.4,5
A previously published series of 20 patients with wound 
botulism suggested that early anti-toxin administration was 
associated with lower frequency and shorter duration of 
mechanical ventilation.6 Additional evidence from a study of 
132 patients with food botulism suggests lower fatality and 
shorter disease course from early anti-toxin administration.1,7
Although wound botulism is a rare disease, it causes 
severe disability and potential for adverse outcomes. The 
treatment frequently entails prolonged hospitalization, 
consumption of scarce medical resources, and high healthcare 
costs. It is possible that early identification and intervention by 
emergency physicians (EPs) may influence hospital course of 
care and outcomes in these cases.
Goals of this Investigation
We sought to describe the characteristics of injection drug 
users (IDUs) with wound botulism and to identify factors 
associated with need for mechanical ventilation, length of 
intensive care unit (ICU) stay, length of hospital stay, hospital-
related complications, and death. We hypothesized that early 
anti-toxin administration is associated with improved patient 
outcomes.
METHODS
We conducted a retrospective review examining parenteral 
drug abusers admitted to any of three University of California 
hospitals (UC Davis Medical Center, Sacramento, CA; UC 
San Francisco Medical Center, San Francisco, CA; and UC 
San Diego Medical Center, San Diego, CA) with a diagnosis 
of wound botulism between 1991-2005. This study was 
approved with exemption from formal review by each hospital’s 
respective institutional review board. Patients were identified 
by a search for hospital discharges with an ICD-9 code for 
“Botulism” (005.1) and a review of hospital pharmacy records 
for patients who received botulinum antitoxin during the 
study period. Patients were included who had a documented 
history of IDU and a confirmed diagnosis of wound botulism. 
Confirmation of wound botulism, required subjects to have: 1) 
Symptoms consistent with wound botulism (bulbar palsy and/
or peripheral weakness), and 2) A confirmatory test, including 
serum detection of botulinum toxin by bioassay or polymerase 
chain reaction (PCR); electromyography (EMG) findings 
consistent with botulism; and/or isolation of C. botulinum from 
wound culture. Pediatric patients (<18 years) and those with 
incomplete medical records were excluded.
Study definitions were determined a priori. Three 
abstractors recorded data from medical records onto a 
standardized data collection instrument. Inter-rater reliability 
of the abstractors was not measured. At the time of data 
collection, abstractors were not blinded to outcome variables, 
however emergency department (ED) records were abstracted 
prior to review of hospitalization data. Data collected from 
the ED record included: patient’s chief complaint, initial 
vital signs, symptoms, history of illicit drug use, physical 
examination findings, initial laboratory values, initial 
chest radiograph findings, negative inspiratory force (NIF) 
measurement, and ED interventions (oxygen administration, 
mechanical ventilation, antibiotic administration, anti-toxin 
administration, wound incision and drainage). Historical data 
was abstracted from narrative sections of the medical record.
The presence and timing of the following variables were 
documented from the hospital admission records: time from 
ED presentation to antitoxin administration in hours, length of 
ICU stay in hours, length of hospital stay in hours, length of 
mechanical ventilation in hours, length of time to incision and 
drainage (I&D) in hours, time to antibiotic administration in 
hours, chest radiograph findings for pneumonia, and hospital-
related complications. Patients transferred to an outside hospital 
or nursing facility were excluded from hospital length of stay 
analyses as it was not feasible to document the length of stay 
in these patients. Hospital-related complications were defined 
as: the development of hospital-acquired pneumonia; venous 
line infections; pneumothorax during mechanical ventilation; 
development of a decubitus ulcer; development of venous 
thromboembolic disease, including deep venous thrombosis 
and pulmonary embolus; C. difficile colitis; and medication 
allergy. Pneumonia was defined by chest radiograph finding of 
infiltrate (by radiology report) with a documented diagnosis of 
“pneumonia” in the clinical notes. Hospital-acquired pneumonia 
was defined as pneumonia that was discovered after a normal 
ED chest radiograph.
Primary outcome variables were the need for mechanical 
ventilation (either endotracheal intubation or noninvasive 
ventilation), length of ICU stay, length of hospital stay, 
hospital-related complications, and death. 
Data analysis
The study population was described using simple 
descriptive statistics. Continuous variables are presented as 
the mean ± one standard deviation for normally distributed 
variables and as the median with inter-quartile ranges 
(IQR) for variables with non-normal distribution Ninety-
five percent confidence intervals (CI) are presented where 
appropriate. Differences in outcomes for continuous 
variables are compared using the Mann-Whitney two-sample 
test. Relationships between continuous variables and the 
outcomes of interest were measured using single variable 
linear regression analysis. Data analysis was performed with 
Stata statistical software (Release 8.0. College Station, TX: 
Stata Corporation; 2004). 
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RESULTS
Characteristics of Study Subjects
Seventy-two patients with an ICD-9 diagnosis of 
“Botulism” or receiving botulism anti-toxin were identified. 
Forty-three cases were excluded because patients were 
diagnosed with other forms of botulism (15); alternative 
neuromuscular diseases (5); or medical records were 
unavailable (23). Twenty-nine (59%) patients met study 
inclusion criteria. Case distribution was as follows: UC Davis 
Medical Center, 17 (59%); UC San Francisco Medical Center, 
10 (34%); and UC San Diego Medical Center, two (7%). 
The cohort consisted of 21 males (72%) and eight females 
with a mean age of 45.3 ± 7.9 years. A history of IDU was 
documented in all cases. IDU was reported as heroin by 22 
patients (76%) and heroin and methamphetamine by seven 
(24%). The reported route of injection drug administration 
was solely subcutaneous (“skin popping”) in 16 (55%); 
solely intravenous in three (10%); and both intravenous and 
subcutaneous in 10 (34%). Data regarding other reported 
routes of drug use was not collected.
Wound botulism diagnosis was confirmed by bioassay 
in 14 (48%) patients; PCR in one (4%); EMG in 18 (62%); 
and wound culture in three (10%). Botulinum toxin type was 
documented in 16 (55%) cases. Toxin type was type A in 14 
(88%) patients, type B in one patient, and “type A & B” in one 
patient. This last type likely refers to a botulinum confirmation 
test that did not differentiate type A from type B.
Main Results
The most commonly recorded ED chief complaints 
were visual changes (13), including double vision (9) and 
blurry vision (4). Other chief complaints were weakness (9), 
difficulty swallowing (7), shortness of breath (4), speech 
changes (4) (including slurred speech [2] and difficulty 
speaking [2]), and dizziness (3). Sore throat, numbness, ptosis, 
arm & tongue heaviness, and altered mental status were 
reported in 1 patient each.
ED symptoms as reported by patients are presented 
in Table 1. The most common recorded symptoms were 
visual changes, speech changes, difficulty swallowing, and 
generalized weakness. All patients complaining of wound 
or extremity pain were found to have a soft tissue abscess. 
Five of the 22 patients with soft tissue wounds documented 
on physical examination did not have wound/extremity 
pain documented on presentation. ED physical examination 
findings are presented in Table 2. One patient did not have 
any documented ED physical examination. Vitals signs upon 
presentation were unremarkable, except for three patients with 
hypoxia by pulse oximetry, one with tachypnea, and one with 
bradypnea. No patient had a documented fever (>38°C) on 
presentation. Every patient in our sample received a complete 
blood count and chemistry panel in the ED. There were no 
laboratory abnormalities requiring therapeutic intervention. 
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Table 1. Symptoms at emergeny department (ED) presentation (n=29)*^
Symptoms Cases / Total Percentage
Bulbar symptoms
Double vision / diplopia 24 / 25 92%
Blurry vision 18 / 22 82%
Difficulty swallowing 20 / 24 83%
Voice / speech problems 13 / 15 87%
Neurological symptoms
Generalized weakness 21 / 23 91%
Shortness of breath 17 / 28 61%
Focal weakness 9 / 20 45%
Constitutional symptoms
Vomiting or diarrhea 3 / 26 12%
Dizziness 10 / 19 53%
Fainting or syncope 0 / 13   0%
Wound-related symptoms
Fever 3 / 26 12%
Extremity / wound pain 12 / 20 60%
* Symptoms as reported by the patient during ED presentation.
^ Cases were not included in the denominator if the data was 
missing in the medical record.
Table 2. Physical examination findings at presentation (n=29)*^
Findings Cases / Total Percentage
Bulbar palsy 25 / 28 89%
Extraocular muscle palsy 19 / 28 68%
Ptosis 17 / 27 63%
Dysarthria 18 / 22 82%
Other cranial nerve abnormality 14 / 28 50%
Abnormal gag 6 / 27 18%
Abnormal pupillary exam 5 / 28 18%
Symmetric motor weakness 16 / 27 59%
Focal motor weakness 9 / 28 32%
Hyporeflexia 7 / 25 28%
Skin wound / abscess 22 / 29 76%
Pneumonia on chest radiograph 9 / 27 33%
* Physical examination findings as recorded by the examining 
physicians in the emergency department record.
^ Cases were not included in the denominator if the data was 
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Data regarding blood cultures was not collected. Further 
data regarding each patient’s clinical course and treatment is 
provided in Table 3, available at http://escholarship.org/uc/
uciem_westjem under supporting material for the article.
The median length of hospital stay was 628 hours (26.2 
days) (IQR 192-1080 hours). Seven patients were discharged 
to an outside healthcare facility and one had no time of 
discharge recorded; therefore, complete data on hospital 
length of stay is not available. These eight patients were 
excluded from the hospital length of stay analysis only.
The median length of ICU stay was 348 hours (14.5 days) 
(IQR 51-716 hours). Twenty-one (72%, 95% CI 53-87%) 
patients were treated with mechanical ventilation. Length of 
ICU stay in patients who underwent mechanical ventilation 
was longer [636.6 hours (26.5 days); 95% CI 456.4-816.8 
hours] than those without mechanical ventilation [36.4 hours 
(1.5 days); 95% CI 9.6-63.2 hours]. Noninvasive ventilation 
was attempted initially in three cases; however, all failed 
and ultimately underwent endotracheal intubation. Twenty 
hospital complications were documented in 13 patients. All 
complications occurred in mechanically ventilated patients 
(62% of intubated patients had a complication). Complications 
included: hospital-acquired pneumonia (10); C. difficile colitis 
(4); antitoxin allergy (2); pneumothorax (1); venous line 
infection (1; decubitus ulcer (1); venous thromboembolism 
(1). No patient (0%, 95% CI 0-10%) died. 
Six patients (21%, 95% CI 8-40%) reported a previous 
presentation to a healthcare facility related to this illness. 
Those patients with a preceding presentation to a healthcare 
facility (missed diagnosis) did not have a higher rate of 
mechanical ventilation (4/6, 67%; 95% CI 22-97% versus 
17/23, 74%; 95% CI 52-90%).
Botulinum antitoxin was administered to 26 (90%) 
patients. Each of these patients received a single vial of 
antitoxin. The median time to antitoxin administration was 
15.3 hours (IQR 8-42 hours). Only two patients received 
antitoxin in the ED. The median time from hospital 
presentation to antitoxin administration was 16 hours (IQR 
8-47 hours) in the MV group and 12 hours (IQR 7.5-29 hours) 
in the non-MV group (p=0.54). Linear regression analysis of 
the time from presentation to antitoxin administration versus 
length of ICU stay showed a highly significant relationship 
(Regression coefficient = 2.5; 95% CI 0.45-4.5; p=0.02). 
Two of the 26 patients (7.7%; 95% CI 0.9-25.1) receiving 
antitoxin had a documented allergic reaction. Both patients 
were intubated prior to antitoxin allergy. One was described 
as “mild” and the other “severe.” The mean time from 
presentation to antitoxin administration in the two patients 
who received antitoxin in the ED was 6.25 hours (95% CI = 
3.8-8.7 hours) versus 44.65 hours (95% CI = 13.0-76.3 hours) 
in those patients not receiving antitoxin in the ED. 
All 29 patients (100%) were treated with intravenous 
antibiotic medications during their hospitalization. The median 
time to antibiotics was 11 hours (IQR 4-22 hours). Linear 
regression analysis of time to antibiotics therapy versus ICU 
length of stay showed no significant relationship (Regression 
coefficient = -1.4; 95% CI -5.8-3.0; p=0.52)
Incision and drainage of a skin abscess was performed in 
17 patients (59%). Of these, 15 had the time to wound incision 
and drainage documented. The median time to incision and 
drainage was 17 hours (IQR 9.5-34 hours). Linear regression 
analysis of time to wound incision and drainage versus length 
of ICU stay demonstrated a highly significant relationship 
(Regression coefficient = 13.7; 95% CI = 2.3-25.2; p=0.02).
DISCUSSION
These results demonstrate clinical characteristics of 
patients diagnosed with wound botulism related to IDU. All 
patients reported abusing heroin and the majority reported 
“skin popping” as the main route of administration. Chief 
complaints related to and physical findings of bulbar muscle 
palsy were documented in the majority of cases. In those 
cases without physical examination findings of bulbar palsy 
documented, the patient complaints suggested presence of a 
bulbar palsy in all cases. Nearly three-fourths of our cases had 
a skin wound identified, which is consistent with past series 
of wound botulism.4,6 Essentially all cases with documented 
serum toxin confirmation were found to have type A 
botulinum toxin, which is also consistent with prior reported 
series.1,4 Type A botulinum toxin is the most commonly 
reported serotype in the Western U.S.8
Patients with wound botulism had prolonged 
hospitalization and ICU stays. As expected, those who were 
mechanically ventilated had much longer stays than those not 
requiring mechanical ventilation. Additionally, all hospital-
related complications occurred in the group of ventilated 
patients, with hospital-acquired pneumonia being the most 
common. In this study, we were unable to identify specific risk 
factors associated with patients requiring ventilation versus 
those not. This is unfortunate, as any strategy to prevent 
mechanical ventilation is likely to benefit the patient and 
significantly decrease resource utilization.
We found that the time interval from presentation 
to wound drainage correlated with ICU length of stay. 
Additionally, the time to wound drainage was shorter in 
those patients who did not require ventilation versus those 
requiring ventilation, but due to the limited sample size, 
these differences did not reach statistical significance. These 
associations indicate that early wound drainage may be 
important in decreasing ICU length of stay and resource 
utilization in patients with wound botulism. 
The time from ED presentation to anti-toxin 
administration also correlated with ICU length of stay. 
Additionally, the time to anti-toxin administration was shorter 
in those patients who did not undergo mechanical ventilation 
versus those requiring ventilation, but again these differences 
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did not reach statistical significance due to the small sample 
size. These associations indicate that early administration 
of anti-toxin may be important in decreasing ICU length 
of stay in these patients. Previous studies also suggest the 
importance of early anti-toxin administration in patients with 
wound botulism.1,6,7 Only two patients in our series received 
anti-toxin in the ED. While this finding is not surprising it is 
noteworthy, as the majority of patients in our study were seen 
at a facility that actually stocks botulinum anti-toxin in the 
hospital pharmacy, making ED administration more feasible. 
The delay in anti-toxin administration highlights the difficulty 
of diagnosing wound botulism and administering anti-toxin 
rapidly.
Wound Botulism poisoning is treated with equine-derived 
antitoxin. Bivalent anti-toxin (containing antibodies to type A 
and type B botulinum toxins) is the most commonly available 
formulation in the U.S.8 A trivalent antitoxin (type A, B, and 
E) is also available in certain locations. The antitoxin dosage 
is a single 10 mL vial diluted 1:10 in 0.9% saline administered 
by slow IV infusion. A second vial may be given in 2-4 hours 
if clinical progression is observed, but this is rarely necessary 
as the quantity of neutralizing antibodies within a vial of anti-
toxin usually far exceeds levels of circulating toxin. Antitoxin 
antibodies do not reverse paralysis but instead prevent further 
worsening of symptoms.3,8 For this reason, early antitoxin 
dosing is critical to stop symptom progression before the 
patient becomes severely affected and a prolonged hospital 
course is inevitable.
Unfortunately, the expense and difficulty of 
obtaining botulinum anti-toxin often discourages its early 
administration. A strategy of early, empiric dosing in selected, 
high-risk patients seems warranted and is likely to be 
overall cost-effective. Any IDU presenting to the ED with 
bulbar palsy should be considered for early treatment with 
botulinum anti-toxin.9 The finding of a skin wound should 
further increase suspicion and heighten the speed of anti-toxin 
administration. It is noteworthy that patients with botulism 
may initially present with asymmetric findings.10 Immediate 
testing of blood glucose, electrolytes, cranial CT scan, and 
lumbar puncture will help to rapidly narrow the differential 
diagnosis. Although there are many possible causes of 
symmetric motor neuropathies, both myasthenia gravis and 
the Miller-Fisher variant of Guillain-Barré syndrome may be 
confused with botulism, increasing the diagnostic difficulty.9,10 
Furthermore, false positive edrophonium challenge tests 
(suggesting myasthenia gravis) have been reported in cases of 
wound botulism10 and food-borne botulism9,11,12 causing delays 
in diagnosis and treatment.
When the diagnosis of wound botulism is suspected, 
the process for anti-toxin acquisition should be immediately 
initiated. This requires contacting local (or state) health 
department authorities to facilitate anti-toxin delivery and 
specimen collection for confirmatory testing. Anti-toxin 
administration should generally not be delayed for botulism 
confirmation. Local health departments should contact the 
Centers for Disease Control (CDC) at (770) 488-7100 for 
assistance in acquiring anti-toxin. The CDC website (http://
www.cdc.gov) contains detailed information about botulism 
epidemiology, diagnosis, confirmation, treatment and 
emergency response. 
Although antitoxin administration should not be delayed 
for performance of electrophysiological testing, these studies 
may help to provide further diagnostic clarity while awaiting 
antitoxin acquisition. Characteristic electromyography (EMG) 
patterns have been described in association with botulinum 
toxin poisoning. Therefore, EMG testing may help to diagnose 
botulism or differentiate botulism from myasthenia gravis 
and Guillain-Barré syndrome.1,3,13 Expected findings with 
botulism are normal conduction velocities, small motor-
action potentials, no change with repetitive stimulation, and 
fibrillation potentials with EMG.9,13 When electrophysiological 
testing is performed in the setting of suspected botulism, 
it is highly recommended that detailed descriptions of 
electrodiagnostic findings in botulism be reviewed prior to 
testing.3,14 EMG results are most reliable when performed by a 
person with experience in this procedure.
The criterion standard testing for botulism is the mouse 
bioassay procedure.1 Testing is usually performed for type A 
and type B botulinum toxins, as these are the most common 
toxin types within the U.S. Evaluation for type E toxin may be 
performed routinely in certain areas of the Pacific Northwest 
and Alaska or when a fish source of botulism is suspected.9 
The mouse bioassay is performed by intra-peritoneal injection 
of mice with either pure subject serum or an incubated mixture 
of subject serum and monovalent anti-toxin. Monovalent 
antitoxins (Type A, B, C, D, E, F) are distributed by the CDC 
for testing purposes. Injected mice are then observed for four 
days for signs of botulism poisoning and death. It should be 
noted that although botulism usually kills mice within 6-24 
hours, cases of delayed death are occasionally observed. If 
toxin is present all mice are expected to die, except those 
injected with the mixture containing the involved anti-toxin 
type.8,9 An enzyme-linked immunosorbent assay (ELISA) test 
has also been developed, but is generally not available.9,15
LIMITATIONS
This study is limited by the restrictions inherent to the use 
of retrospective data, including incomplete documentation, 
recording bias, and changes in medical practice that may have 
occurred during the study period. Unfortunately, because 
wound botulism is a rare disease, prospective research in 
this area is difficult. Time estimates for ICU stay, antitoxin 
administration, and hospital stay may not be entirely accurate 
due to the retrospective nature of this study. Further, due 
to the social situations of this patient population, length of 
hospitalization may depend on factors other than medical 
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necessity (e.g. placement, housing, rehabilitation, etc.). All 
study hospitals are academic centers where resident physicians 
are primarily responsible for initial patient evaluations and 
medical record documentation. 
While it is likely that changes in intensive care practices 
did occur during the study period (1991-2005), there have been 
no significant changes in botulism anti-toxin formulation or 
known indications. Unfortunately, it was not feasible to adjust 
for changes in clinical practice over the study period when 
evaluating length of ICU stay and hospital complications. It 
is possible that in patients who were critically ill, drainage 
procedures and antitoxin administration may have been 
deferred in favor of more critical interventions (such as tracheal 
intubation), which could confound the observed associations 
between antitoxin, wound I&D, and ICU length of stay.
Due to the small sample, multivariate analysis to determine 
the independent contribution of multiple variables is not 
feasible. Wound botulism is a rare disease and therefore difficult 
to research. However, our study is the largest series of wound 
botulism cases in which hospital records were reviewed. Almost 
all botulism cases were type A; therefore, our results may not be 
generalizable to other botulinum toxin serotypes.
CONCLUSION
In this series of wound botulism cases, the time from ED 
presentation to antitoxin administration and wound drainage 
both correlated with ICU length of stay. Time of presentation 
to antibiotics was not associated with length of stay. In cases 
of suspected wound botulism, early antitoxin administration 
and wound drainage, possibly while the patient is in the ED, 
may help to decrease ICU length of stay.
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